Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MYMD-1 in Healthy Male Adults
NCT04349761Phase 1Completed
- Sponsor
- TNF Pharmaceuticals, Inc.
- Start
- Jun 2019
- Primary completion
- Dec 2019
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of isomyosamine in Sarcopenia, frailty syndrome, rheumatoid arthritis (RA) and 1 more (5 cohorts), sponsored by TNF Pharmaceuticals, Inc. Primary endpoints: Adverse Events at 5 days, Changes in Physical examination: Neurologic, Cardiovascular, HEENT, General Appearance, Respiratory, Gastrointestinal, Body Weight, Height at 5 days and 15 more. Started Jun 2019; status: completed.
02
Drugs
isomyosamine
03
Conditions
Sarcopeniafrailty syndromerheumatoid arthritis (RA)Hashimoto's thyroiditis
Beyond the preview
Go deeper on NCT04349761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04349761.